Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

Constructive second-quarter operating evidence is offset by an unverified third-quarter earnings trigger. No attributable post-release price reaction or post-print analyst revision was found; the October 20 anchor must not be described as an earnings reaction. The packet's positive deterministic prior supports continued monitoring, not a confirmed thesis upgrade. Sentiment metrics other than headline buzz are unavailable; zero denotes unavailable, not a measured neutral reading.

Treat this as a low-coverage monitoring update, not a confirmed T+3 earnings reaction. The checked company source supports Q2 results, but no October print, post-print price reaction or analyst target revision was verified. Zero-valued sentiment fields indicate unavailable measurements, not neutral readings. The deterministic negative directional prior warrants caution despite the earlier positive baseline.

The company-confirmed print improves on the prior April monitoring baseline, consistent with the deterministic score's positive directional prior, but the follow-through is mixed. [MarketBeat](https://www.marketbeat.com/stocks/NYSE/MTB/earnings/) records a roughly 1.6% decline on October 16, while the packet's October 20 anchor of $218.35 is near the implied pre-release close; the initial decline did not persist through that anchor. Multiple post-print target cuts are available, but a reliable aggregate forward-estimate revision series is not. No sufficient social, options, short-interest or employee-sentiment measurements were supplied; numeric sentiment placeholders should not be interpreted as observations.

Neutral monitoring view. The $17.31 October 20 packet anchor is below the $17.52 October 16 close reported by market coverage, but this is not a post-earnings reaction: Q3 results are scheduled for October 28. [Company IR](https://www.gbankfinancialholdings.com/) No verified Q3 analyst revisions, surprise figures, or transcript are available. Sentiment data fields set to zero above denote unavailable measurements, not observed neutral readings. Earlier August insider purchases are disclosed but do not establish operating improvement. [#SEC-FORM4-2026-08-05] [#SEC-FORM4-2026-08-07]

This T+3 run does not establish that earnings occurred on October 16, so neither an earnings surprise nor an earnings-linked price reaction can be assessed. No post-print analyst revision was verified. The October 20 price anchor of $7.13 is below the cited October 16 close of $7.23, but attributing that move to results would be unsupported. The neutral deterministic prior and stronger Q2 primary evidence justify moving beyond the stale software-shell baseline, while low coverage and limited commercial proof keep the view cautious. [REalloys press releases](https://realloys.com/news-media/press-releases/) [ChartMill](https://www.chartmill.com/stock/quote/ALOY/analyst-ratings)

This is a pre-Q3 monitoring update, not a valid T+3 post-print assessment: Euronet scheduled the release for October 27, after the October 20 price anchor. There is therefore no Q3 earnings surprise, post-release price reaction or post-print analyst revision to interpret. The October 16 Stephens action was pre-release. The positive deterministic directional prior does not overcome the erroneous trigger date or mixed Q2 operating evidence. Numeric sentiment fields are unavailable placeholders, not measured neutral readings. [#PR-EARNINGS-2026-10-14] https://ir.euronetworldwide.com/node/22826/pdf